| Literature DB >> 35169807 |
Daniel Olson, Diva M Calvimontes, Molly M Lamb, Gerber Guzman, Edgar Barrios, Andrea Chacon, Neudy Rojop, Kareen Arias, Melissa Gomez, Guillermo Antonio Bolanos, Jose Monzon, Anna N Chard, Chelsea Iwamoto, Lindsey M Duca, Nga Vuong, Melissa Fineman, Kelsey Lesteberg, David Beckham, Mario L Santiago, Kendra Quicke, Gregory Ebel, Emily Zielinski Gutierrez, Eduardo Azziz-Baumgartner, Frederick G Hayden, Hani Mansour, Kathryn Edwards, Lee S Newman, Edwin J Asturias.
Abstract
We evaluated the clinical and socioeconomic burdens of respiratory disease in a cohort of Guatemalan banana plantation workers. All eligible workers were offered enrollment from June 15â€"December 30, 2020, and annually, then followed for influenza-like illnesses (ILI) through: 1) self-reporting to study nurses, 2) sentinel surveillance at health posts, and 3) absenteeism. Workers with ILI submitted nasopharyngeal swabs for influenza, RSV, and SARS-CoV-2 testing, then completed surveys at days 0, 7, and 28. Through October 10, 2021, 1,833 workers developed 169 ILIs (12.0/100 person-years) and 43 (25.4%) of these ILIs were laboratory-confirmed SARS-CoV-2 (3.1/100 person-years). Workers with SARS-CoV-2-positive ILI reported more anosmia (p<0.01), dysgeusia (p<0.01), difficulty concentrating (p=0.01), and irritability (p=0.01), and greater clinical and well-being severity scores (Flu-iiQ) than test-negative ILIs; they also had greater absenteeism (p<0.01) and lost income (median US$127.1, p<0.01). These results support the prioritization of Guatemalan farm workers for COVID-19 vaccination.Entities:
Year: 2022 PMID: 35169807 PMCID: PMC8845422 DOI: 10.1101/2022.02.07.22270274
Source DB: PubMed Journal: medRxiv
Figure 1.CONSORT Diagram. Summary of cohort enrolled in the AGRI Study in SW Guatemala from June 2020 to October 2021, and followed up through October 10, 2021. Ineligible and non-consenting workers were able to provide multiple reasons for not participating. Only workers who completed the Day 0 (diagnosis) visit were called on Day 7 and Day 28. Follow up visits scheduled for after October 10th, 2021 were considered missing.
Characteristics of cohort participants, Guatemala (n=1,833)
|
| |
| Age in years (mean, SD) | 30.9 (8.7) |
| Male sex, n (%) | 1541 (84.1) |
| Ethnicity, n (%): Ladino | 801 (43.7) |
| Indigenous | 113 (6.2) |
| Other | 3 (0.2) |
| Don’t know | 916 (43.7) |
|
| |
| Obesity (measured BMI> 30 kg/m2), n= 1159 with data | 131 (11.3) |
| Class 1 (BMI 30–<35 kg/m2) | 103 |
| Class 2 (BMI 35–<40 kg/m2) | 24 |
| Class 3 (BMI ≥40 kg/m2) | 4 |
| Kidney disease | 58 (3.2) |
| Blood disorder (e.g., sickle cell disease) | 25 (1.4) |
| Cardiovascular disease (e.g., heart failure, CAD) | 29 (1.6) |
| Diabetes | 27 (1.5) |
| Liver disease | 19 (1.0) |
| Asthma | 10 (0.6) |
| Pulmonary Disease (e.g., COPD) | 10 (0.6) |
| Neurologic disease (e.g., stroke) | 10 (0.6) |
| Taking medications | 234 (12.8) |
| Received influenza vaccine | 108 (5.9) |
|
| |
| Type of Work, n (%) | |
| Administration | 60 (3.3) |
| Field worker | 1264 (69.0) |
| Field manager | 77 (4.2) |
| Packer (plant worker) | 413 (22.5) |
| Plant manager | 19 (1.0) |
| Duration of employment, n (%) | |
| ≤2 years | 1115 (60.9) |
| 3–4 years | 242 (13.2) |
| ≥5 years | 475 (25.9) |
| Monthly income, $USD, median (IQR) | 337.2 (311.3, 389.1) |
|
| |
| # adults in house, median (IQR) | 3 (2–4) |
| # children in house, median (IQR) | 2 (1–3) |
| Concern about food insecurity in last year, n (%) | 1063 (58.0) |
| Household monthly income, $USD, median (IQR) | 363.2 (324.3–505.8) |
| $USD spent in the last 7 days, median (IQR): | |
| Meat, fish, and seafood | 25.9 (13.0–38.9) |
| Milk, eggs, and dairy products | 15.6 (9.7–25.9) |
| Greens, vegetables, and fruit | 13.0 (6.8–19.5) |
| Alcoholic drinks and tobacco | 0 (0–0) |
Abbreviations: SD=standard deviation, BMI=body mass index, CAD=coronary artery disease, IQR=interquartile range, USD=US dollars
Figure 2.Map of the study region (2,600 km2) showing number of enrolled subjects living in each municipality, n=1,819 with reported data.
Figure 3.Cumulative ILI Events in the AGRI Cohort, June 15, 2020 to October 10, 2021. From June 2020–October 2021, ILI was defined as “cough and fever”; in January 2021, the ILI case definition was expanded to “cough or fever or shortness of breath”. Includes all-cause ILI (yellow), SARS-CoV-2-positive ILI (blue), SARS-CoV-2 negative ILI (orange), and ILI without test obtained (gray).
Comparison of Self-Reported Outcomes in SARS-CoV-2-positive ILI vs SARS-CoV-2-negative ILI
| Day 0 SARS-CoV-2 positive | Day 0 SARS-CoV-2 negative | p-value | Day 7 SARS-CoV-2 positive | Day 7 SARS-CoV-2 negative | p-value | Day 28 SARS-CoV-2 positive | Day 28 SARS-CoV-2 negative | p-value | |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| # days of fever (if fever), mean (SD) | 3.3 (2.0) | 2.3 (1.5) | <0.01 | 4.4 (2.8) | 3.3 (2.5) | 0.08 | 0.5 (0.0) | 3.4(2.2) | 0.04 |
| # days of cough (if cough), mean (SD) | 3.3 (1.9) | 3.6 (2.1) | 0.45 | 6.1 (2.3) | 5.1 (2.6) | 0.07 | 4.5 (4.9) | 5.1 (3.5) | 0.84 |
| Have you felt the following (last 24 hours), n (%): | |||||||||
| Fever | 32 (74.4) | 60 (54.6) | 0.02 | 2 (4.9) | 11 (10.8) | 0.35 | 4 (10.5) | 4 (4.2) | 0.22 |
| Nasal Congestion | 18 (41.9) | 39 (35.5) | 0.46 | 5 (12.2) | 17 (16.7) | 0.50 | 2 (5.3) | 6 (6.3) | 1.00 |
| Myalgia | 23 (53.5) | 46 (41.8) | 0.19 | 3 (7.3) | 10 (9.8) | 0.76 | 5 (13.2) | 6 (6.3) | 0.19 |
| Headache | 30 (69.8) | 55 (50.0) | 0.03 | 13 (31.7) | 21 (20.6) | 0.16 | 8 (21.1) | 14 (14.6) | 0.36 |
| Cough | 24 (55.8) | 39 (35.5) | 0.02 | 7 (17.5) | 14 (13.7) | 0.57 | 3 (7.9) | 7 (7.3) | 1.00 |
| Sore Throat | 15 (34.9) | 50 (45.5) | 0.23 | 6 (14.6) | 14 (13.7) | 0.89 | 4 (10.5) | 7 (7.3) | 0.51 |
| Dysgeusia | 21 (48.8) | 27 (24.6) | <0.01 | 8 (19.5) | 6 (5.9) | 0.01 | 3 (7.9) | 2 (2.1) | 0.14 |
| Expectoration | 16 (37.2) | 45 (40.9) | 0.67 | 12 (29.3) | 18 (17.7) | 0.12 | 7 (10.5) | 8 (8.3) | 0.74 |
| Fatigue | 24 (55.8) | 30 (27.3) | <0.01 | 7 (17.1) | 11 (10.8) | 0.31 | 6 (15.8) | 5 (5.2) | 0.04 |
| Anosmia | 19 (44.2) | 19 (17.3) | <0.01 | 9 (22.0) | 3 (2.9) | <0.01 | 3 (7.9) | 2 (2.1) | 0.14 |
| Loss of Appetite | 17 (39.5) | 31 (28.2) | 0.17 | 4 (9.8) | 5 (4.9) | 0.28 | 1 (2.6) | 2 (2.1) | 1.00 |
| Dyspnea | 13 (30.2) | 25 (22.9) | 0.35 | 4 (9.8) | 5 (4.9) | 0.28 | 4 (10.8) | 1 (1.0) | 0.02 |
| Neck Pain | 14 (33.3) | 18 (16.4) | 0.02 | 6 (14.6) | 5 (4.9) | 0.05 | 4 (10.5) | 4 (4.2) | 0.22 |
| Interrupted Sleep | 11 (25.6) | 19 (17.3) | 0.24 | 8 (19.5) | 6 (5.9) | 0.01 | 3 (7.9) | 4 (4.2) | 0.40 |
| Wheezing | 4 (9.5) | 14 (12.7) | 0.78 | 1 (2.4) | 5 (4.9) | 0.67 | 4 (10.5) | 1 (1.0) | 0.02 |
|
| |||||||||
| Have you had difficulty with (last 24 hrs), n (%): | |||||||||
| Getting out of bed | 16 (37.2) | 26 (23.6) | 0.09 | 5 (12.2) | 4 (3.9) | 0.12 | 2 (5.3) | 4 (4.2) | 1.00 |
| Preparing meals… | 8 (18.6) | 10 (9.1) | 0.10 | 3 (7.3) | 1 (1.0) | 0.07 | 2 (5.3) | 2 (2.1) | 0.32 |
| Performing usual… | 16 (37.2) | 27 (24.6) | 0.12 | 4 (9.8) | 3 (2.9) | 0.10 | 3 (7.9) | 3 (3.1) | 0.35 |
| Leaving the home… | 13 (30.2) | 14 (12.7) | 0.01 | 6 (14.6) | 0 (0) | <0.01 | 2 (5.3) | 2 (2.1) | 0.32 |
| Concentrating on… | 18 (41.9) | 23 (20.9) | 0.01 | 4 (9.8) | 2 (2.0) | 0.06 | 2 (5.3) | 5 (5.2) | 1.00 |
| Taking care of… | 16 (37.2) | 13 (11.7) | <0.01 | 4 (9.8) | 0 (0) | 0.01 | 2 (5.3) | 4 (4.2) | 1.00 |
| Leave the room | 9 (20.9) | 14 (12.7) | 0.20 | 4 (9.7) | 0 (0) | 0.01 | 2 (5.3) | 2 (2.1) | 0.32 |
| Have you felt the following (last 24 hours), n (%): | |||||||||
| Irritable | 25 (58.1) | 37 (33.6) | 0.01 | 4 (9.8) | 8 (7.8) | 0.74 | 4 (10.5) | 6 (6.3) | 0.47 |
| Defenseless | 18 (41.9) | 20 (18.2) | <0.01 | 5 (12.2) | 5 (4.9) | 0.12 | 3 (7.9) | 3 (3.1) | 0.35 |
| Worried | 19 (44.2) | 35 (31.8) | 0.15 | 13 (31.7) | 8 (7.8) | <0.01 | 5 (13.2) | 10 (10.4) | 0.65 |
| Frustrated | 15 (34.9) | 16 (14.6) | <0.01 | 3 (7.3) | 6 (5.9) | 0.72 | 2 (5.3) | 5 (5.2) | 1.00 |
| People worrying. | 30 (69.8) | 57 (51.8) | 0.04 | 18 (43.9) | 21 (20.6) | <0.01 | 11 (29.0) | 18 (18.8) | 0.20 |
| Being a burden | 13 (30.2) | 30 (27.3) | 0.71 | 9 (22.0) | 10 (9.8) | 0.05 | 5 (13.2) | 9 (9.4) | 0.52 |
| People being. | 13 (30.2) | 24 (21.8) | 0.27 | 8 (19.5) | 8 (7.8) | 0.05 | 7 (18.4) | 7 (8.3) | 0.10 |
| Needing to depend. | 16 (37.2) | 23 (20.9) | 0.04 | 10 (24.4) | 9 (8.8) | 0.01 | 6 (15.8) | 10 (10.4) | 0.39 |
| People having to do extra. | 15 (34.9) | 21 (19.1) | 0.04 | 10 (24.4) | 10 (9.8) | 0.02 | 8 (21.1) | 8 (8.3) | 0.04 |
|
| |||||||||
| Systemic Score | 0.87 (0.68) | 0.52 (0.55) | <0.01 | 0.21 (0.35) | 0.12 (0.24) | 0.19 | 0.13 (0.31) | 0.09 (0.28) | 0.41 |
| Respiratory Score | 0.50 (0.43) | 0.47 (0.45) | 0.64 | 0.16 (0.28) | 0.16 (0.32) | 0.99 | 0.14 (0.4) | 0.08 (0.21) | 0.41 |
| Impact on Daily Activities | 0.50 (0.85) | 0.22 (0.40) | 0.01 | 0.14 (0.40) | 0.02 (0.08) | 0.05 | 0.06 (0.21) | 0.04 (0.20) | 0.71 |
| Impact on Emotions Score | 0.62 (0.57) | 0.31 (0.45) | <0.01 | 0.17 (0.34) | 0.07 (0.22) | 0.09 | 0.20 (0.24) | 0.08 (0.23) | 0.60 |
| Impact on Others Score | 0.65 (0.65) | 0.44 (0.64) | 0.08 | 0.37 (0.52) | 0.16 (0.40) | 0.03 | 0.25 (0.47) | 0.16 (0.41) | 0.27 |
|
| |||||||||
| # in house w/ similar illness (last 2 weeks) | 0.30 (0.64) | 0.13 (0.36) | 0.10 | 0.34 (0.62) | 0.17 (0.49) | 0.09 | 0.11 (0.39) | 0.14 (0.41) | 0.61 |
| Index case in house, n (%) | |||||||||
| Self | 35 (81.4) | 97 (88.2) | 34 (82.9) | 96 (94.1) | 33 (86.8) | 90 (93.8) | |||
| Spouse | 2 (4.7) | 3 (2.7) | 1 (2.4) | 1 (1.0) | 1 (2.6) | 1 (1.0) | |||
| Parent | 0 (0) | 2 (1.8) | 0.13 | 1 (2.4) | 1 (1.0) | 0.10 | 0 (0) | 0 (0) | 0.24 |
| Sibling | 3 (7.0) | 3 (2.7) | 3 (7.3) | 2 (2.0) | 3 (7.9) | 3 (3.1) | |||
| Cousin | 1 (2.3) | 0 (0) | 1 (2.4) | 0 (0) | 0 (0) | 0 (0) | |||
| Child | 0 (0) | 4 (3.6) | 0 (0) | 1 (1.0) | 0 (0) | 2 (2.1) | |||
p-values are from t-tests for continuous variables, and chi-square test for categorical variables.
Items truncated per Flu-iiQ licensing agreement; full items available from the author.
Higher scores indicate worse outcomes
Figure 4.Flu-iiQ severity scores (range: 0–3), by subdomain, for workers with SARS-CoV-2-positive influenza-like illness (ILI), SARS-CoV-2-negative ILI, and asymptomatic controls. Higher score indicates greater clinical severity (Panels A and B) or greater negative impact on well-being (Panels C-E). Significant differences (p<0.05) are identified within each group. Blue=SARS-CoV-2-positive ILI, orange=SARS-CoV-2-negative ILI, gray=asymptomatic controls.
Figure 5.Differences in expenditures between SARS-CoV-2-positive and -negative workers with influenza-like illness (ILI). Workers with SARS-CoV-2-positive ILI (dark blue circle) reported significantly greater lost income and combined expenditures related to their illnesses in the week following their illness than SARS-CoV-2-negative workers with ILI (orange circle).